Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neumora Therapeutics, Inc. filings document the regulatory record for a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies that target novel mechanisms of action. The company’s 8-K reports furnish financial results, business updates, corporate presentations, and clinical-development disclosures for programs including navacaprant, NMRA-511, NMRA-898, NMRA-861, and NMRA-215.
Neumora’s SEC filings also cover proxy governance, executive compensation, board and shareholder voting matters, registered common stock, and capital-structure events. Recent disclosure areas include Regulation FD presentations, unregistered equity issuance tied to a loan conversion right, and formal exhibits that describe program plans, financing arrangements, risk statements, and public-company reporting obligations.
Neumora Therapeutics reported that its Phase 3 KOASTAL‑2 and KOASTAL‑3 trials of navacaprant in major depressive disorder failed to achieve statistical significance on primary or key secondary endpoints, and the company is discontinuing development of navacaprant. KOASTAL‑2 and KOASTAL‑3 enrolled 430 and 422 adult patients, respectively, and showed similar or numerically worse depression score changes versus placebo.
Neumora is implementing a workforce reduction of approximately 35%, expecting about $10 million in annualized cost savings, partially offset by about $2 million in one‑time restructuring costs in the second quarter of 2026. Following these changes, the company expects its current cash and cash equivalents to provide runway into the third quarter of 2027 while it focuses on NMRA‑511 in Alzheimer’s disease agitation, NMRA‑898 in schizophrenia and NMRA‑215 in cardiometabolic disease. Neumora also entered a Third Amendment to its Loan and Security Agreement, extending the interest‑only period and revising a minimum liquidity covenant tied to milestones and market capitalization.
Neumora Therapeutics, Inc. director and 10% owner Kristina Burow received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036.
According to the grant terms, 100% of the shares subject to the option vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date. After this grant, the filing shows 80,000 derivative securities held directly.
Neumora Therapeutics director Matthew K. Fust received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting after that date. Following this compensation award, Fust holds 80,000 derivative securities directly.
Neumora Therapeutics director David Piacquad received a grant of stock options for 80,000 shares of Common Stock at an exercise price of $1.86 per share. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date, and expire on May 26, 2036.
Neumora Therapeutics, Inc. director Alaa Halawa received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 option shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date.
Neumora Therapeutics director Ho Maykin received a grant of stock options for 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date.
Neumora Therapeutics, Inc. reported results from its annual meeting of stockholders. Three Class III directors — Paul L. Berns, Matthew Fust and David Piacquad — were elected to serve until the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers and supported holding future advisory votes on executive pay every year. The voting was based on 182,688,076 common shares outstanding and entitled to vote as of the April 7, 2026 record date.
Neumora Therapeutics, Inc. Schedule 13G/A reports that K2 HealthVentures Equity Trust LLC and its managing members, Parag Shah and Anup Arora, may be deemed to beneficially own 5,790,453 shares of Common Stock as of March 31, 2026. These shares represent approximately 3.1% of the class based on 182,157,466 shares outstanding as of March 31, 2026 plus the 5,790,453 conversion shares added under Rule 13d-3(d)(1)(i). The disclosed position reflects conversion rights under a Loan and Security Agreement and an amendment; K2HV Equity may acquire the shares within 60 days upon conversion of outstanding debt obligations.
Neumora Therapeutics, Inc. reported a net loss of $53.5M for the quarter ended March 31, 2026, narrower than the prior-year period. Operating expenses fell to $52.9M as both research and development and general and administrative costs declined.
The company ended the quarter with $147.1M in cash and cash equivalents and believes this will fund operations for at least 12 months from issuance of the statements. Net cash used in operating activities was $46.4M, partly offset by $10.9M of proceeds from at-the-market stock sales.
Neumora remains a clinical-stage biotech with no product revenue, advancing multiple brain-focused programs. Its lead asset, navacaprant for major depressive disorder, is in Phase 3, with KOASTAL-2 and KOASTAL-3 topline data expected in the second quarter of 2026. Additional readouts for NMRA-511 and NMRA-898 are planned for the second half of 2026.
Neumora Therapeutics reported first quarter 2026 results, highlighting lower operating expenses and an extended cash runway as it advances its neuroscience pipeline. Research and development expenses fell to $38.6 million from $52.2 million a year earlier, while general and administrative expenses decreased to $14.3 million from $18.8 million.
Net loss narrowed to $53.5 million, compared with $68.0 million in the first quarter of 2025, with loss per share improving to $0.30 from $0.42. Neumora ended March 31, 2026 with $147.1 million in cash and cash equivalents, which it expects will fund its operating plan into the third quarter of 2027 while it progresses navacaprant, NMRA‑511, NMRA‑898 and NMRA‑215 through key clinical milestones.